Sanofi to Acquire Vigil Neuroscience, Expanding Alzheimer's Treatment Pipeline with VG-3927
Reuters
May 22
<a href="https://laohu8.com/S/GCVRZ">Sanofi</a> to Acquire Vigil Neuroscience, Expanding Alzheimer's Treatment Pipeline with VG-3927
Sanofi SA has announced an agreement to acquire Vigil Neuroscience, Inc., a clinical-stage biotechnology company specializing in therapies for neurodegenerative diseases. This acquisition will bolster Sanofi's neurology pipeline by introducing VG-3927, an investigational medicine aimed at treating Alzheimer's disease. The transaction is valued at approximately $470 million, with Vigil's shareholders receiving $8 per share in cash and a contingent value right for an additional $2 per share, dependent on the first commercial sale of VG-3927. The deal is expected to close in the third quarter of 2025, aligning with Sanofi's strategic focus on innovation in critical healthcare areas. Notably, VGL101, another molecule program from Vigil, will not be part of this acquisition.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sanofi SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001098215-en) on May 21, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.